Daniel Y.C. Heng

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology · 2009 · 2.1K citations · Full text

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · The Lancet Oncology · 2013 · 1K citations · Full text

External Validation, Urology, Population-based Study +9

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 927 citations · Full text

Urology, Genitourinary Cancer, Kidney Research +8

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 763 citations · Full text

Urology, Genitourinary Cancer, Medicine +8